SCHEMBL3433824

SCHEMBL3433824

FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)N1C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3432954 1.00 LMNA (0.31) LMNA
SCHEMBL9446877 0.98
SCHEMBL10948995 0.98 LMNA (0.32) LMNA
SCHEMBL9774510 0.87
SCHEMBL9127392 0.87
SCHEMBL11783987 0.85 LMNA (0.30) LMNA
SCHEMBL10591158 0.82
SCHEMBL3433017 0.77
SCHEMBL3435200 0.77
SCHEMBL9446874 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100055067-A1 PERFLUOROCARBON CONJUGATE AS A BLOOD SUBSTITUTE SNU R&DB FOUNDATION 2010-03-04 US claimed
US-20100055067-A1 PERFLUOROCARBON CONJUGATE AS A BLOOD SUBSTITUTE SNU R&DB FOUNDATION 2010-03-04 US disclosed
US-5262442-A Fluosol for injection for oxygen transport ALPHA THERAPEUTIC CORPORATION (US) 1993-11-16 US disclosed
EP-0548601-A1 Process for rapid thawing and storage of frozen fluorocarbon emulsion, and resultant product ALPHA THERAPEUTIC CORPORATION (US) 1993-06-30 EP disclosed
EP-0282948-B1 STABLE FLUOROCARBON AQUEOUS EMULSIONS AIR PRODUCTS AND CHEMICALS, INC. (US) 1993-01-20 EP disclosed
EP-0282949-B1 CONCENTRATED STABLE FLUORCHEMICAL AQUEOUS EMULSIONS AIR PRODUCTS AND CHEMICALS, INC. (US) 1992-05-20 EP disclosed
US-5114932-A Hyperosmolar oxyreplete hemosubstitute RUNGE THOMAS M (US) 1992-05-19 US disclosed
EP-0220153-B1 A NUTRITIVE EMULSION HAVING OXYGEN-TRANSPORTING PROPERTIES, AND PROCESS FOR ITS PREPARATION Kabi Pharmacia AB (SE) 1991-07-24 EP disclosed
US-4895876-A ARTIFICIAL BLOOD, ORGAN PRESERVATION AIR PRODUCTS AND CHEMICALS, INC. (US) 1990-01-23 US disclosed
US-4866096-A Stable fluorochemical aqueous emulsions AIR PRODUCTS AND CHEMICALS, INC. (US) 1989-09-12 US disclosed
EP-0282948-A2 Stable fluorocarbon aqueous emulsions AIR PRODUCTS AND CHEMICALS, INC. (US) 1988-09-21 EP disclosed
EP-0282949-A2 Concentrated stable fluorchemical aqueous emulsions AIR PRODUCTS AND CHEMICALS, INC. (US) 1988-09-21 EP disclosed
EP-0220153-A1 A nutritive emulsion having oxygen-transporting properties, and process for its preparation Kabi Pharmacia AB (SE) 1987-04-29 EP disclosed
EP-0033402-B1 PERFUSATE FOR PRESERVING ORGAN TO BE TRANSPLANTED AND PRESERVING METHOD The Green Cross Corporation (JP) 1983-09-07 EP disclosed
US-4285928-A AN EMULSION OF AN X-RAY CONTRAST AGENT AND A MIXTURE OF PERFLUORO COMPOUNDS HAVING OXYGEN-CARRYING ABILITIES Wada, Juro (JP) 1981-08-25 US disclosed
EP-0033402-A1 Perfusate for preserving organ to be transplanted and preserving method The Green Cross Corporation (JP) 1981-08-12 EP disclosed
US-4252827-A PERFLUORODECALIN AND PERFLUOROTRIPROPYLAMINE; ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER; PHOSPHOLIPID; FATTY ACID, SALT OR MONOGLYCERIDE THE GREEN CROSS CORPORATION (JP) 1981-02-24 US disclosed
US-4186253-A RINGER'S SOLUTION WITH INCREASED POTASSIUM ION, ALBUMIN, PERFLUOROCARBON COMPOUND, EMULSIFIER THE GREEN CROSS CORPORATION (JP) 1980-01-29 US disclosed
US-3993581-A WITH A PHOSPHOLIPID AS EMULSIFIER AND A FATTY ACID, ALKALI METAL SALT OR ITS MONOGLYCERIDE AS AN ADJUVANT THE GREEN CROSS CORPORATION (JA) 1976-11-23 US disclosed
US-3962439-A PERFLUOROCARBON COMPOUNDS THE GREEN CROSS CORPORATION (JA) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100055067-A1 PERFLUOROCARBON CONJUGATE AS A BLOOD SUBSTITUTE FGB, CD47, PF4 LMNA 2421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.